Clinical Trials Directory

Trials / Completed

CompletedNCT04765501

Cross-cultural Adaptation, Reliability and Validity of the Turkish Version of the Headache Impact Questionnaire

Status
Completed
Phase
Study type
Observational
Enrollment
102 (actual)
Sponsor
Gazi University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to investigate cultural adaptation, reliability and validity of the Turkish version of the Headache Impact Questionnaire (HIQ).

Detailed description

The episodic nature of migraine attacks presents a number of difficulties in characterizing disease severity. There are differences in the severity, frequency and intensity of attacks and the general effect of the disease in individuals. Information about any particular attack is not sufficient to characterize the overall severity of the disease. Accordingly, the Headache Impact Questionnaire (HIQ) was developed to evaluate the headache experience over a period of time instead of any headache. Developed to measure the impact and quality of life of individuals suffering from headache, hıq evaluates the frequency and duration of headache, the degree of pain severity, daily life activities, disruptions in work or school life, the influence of the individual's leisure activities and other symptoms that may occur. HIQ consists of 16 items and the higher the score shows the seriousness of the impact. The study is planned with 80 individuals with complaint of headache. After questioning the sociodemographic characteristics of the individuals, the patients will be asked to fill in HIQ, Migraine Disability Assessment Questionnaire, Headache Impact Test-6 and Short Form-36.Test-retest will be re-applied to those of the same individuals who can be reached after 1 week. The results will be analyzed using the SPSS version 22.0 computer package program.

Conditions

Interventions

TypeNameDescription
OTHERSurvey studyHeadache Impact Questionnaire (HIQ) will be applied.

Timeline

Start date
2022-11-01
Primary completion
2023-09-01
Completion
2024-09-01
First posted
2021-02-21
Last updated
2025-04-08

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT04765501. Inclusion in this directory is not an endorsement.